GlassScriptPhysician profile
Sujung Park
NPI 1811218621
$1,432.04
in general payments reported to CMS, 2019-2025
30 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $133 · 2021: $68.93 · 2022: $55.76 · 2023: $54.17 · 2024: $313 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.80 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.19 | 2020-2025 | Enhertu, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $210.16 | 2021-2025 | |
| Kite Pharma, INC. | $99.00 | 2019 | |
| Incyte Corporation | $83.26 | 2020-2025 | Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $80.80 | 2020-2025 | Opdivo |
| Pfizer INC. | $72.63 | 2023-2025 | |
| Gilead Sciences, INC. | $71.83 | 2021-2025 | Trodelvy |
| Genmab U.S., INC. | $58.01 | 2024-2025 | Epkinly |
| Kyowa Kirin, INC. | $41.57 | 2024-2025 | Poteligeo |
| Genzyme Corporation | $40.68 | 2025 | |
| Puma Biotechnology, INC. | $39.49 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.42 | 2024-2025 | Keytruda, Welireg |
| Ipsen Biopharmaceuticals, INC | $28.77 | 2025 | Onivyde |
| Celgene Corporation | $28.57 | 2025 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.25 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $22.75 | 2025 | Revuforj |
| Genentech USA, INC. | $22.28 | 2025 | Polivy |
| Beone Medicines USA, INC. | $21.98 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $21.34 | 2025 | Xpovio |
| Astellas Pharma US INC | $20.72 | 2025 | Vyloy |
| Eisai INC. | $19.18 | 2025 | |
| Recordati_rare_diseases_inc. | $18.73 | 2024 | Sylvant |
| Beigene USA, INC. | $17.45 | 2020 | |
| Epizyme, INC. | $17.40 | 2021 | |
| Stemline Therapeutics INC. | $17.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Janssen Biotech, INC. | $16.58 | 2019 | |
| Amgen INC. | $16.39 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $15.56 | 2020 | |
| Seagen INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujung Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.